Key Highlights

● Second-quarter revenue fell 27.6% to $76.4 million with a diluted loss of $0.28 per share.

● Independent active earning coaches fell 48.7% to 11,700 while revenue per active coach rose 41.0%.

● Cash, cash equivalents and investment securities totaled $169.8 million and the company reported no debt.

Medifast (NYSE:MED) is in focus on Monday as the weight-management and health company works through a turnaround while keeping a close eye on spending. With revenue sharply lower than a year ago, the question for many market watchers is how capital allocation, cost cuts and a rebrand might interact.

Latest Company Context

Medifast reported second quarter 2026 results on August 3, 2026. Revenue was $76.4 million, down 27.6% from $105.6 million a year earlier, and the company posted a diluted loss of $0.28 per share, a net loss of $3.1 million, compared with earnings of $0.22 per share in the prior-year quarter. Independent active earning coaches fell 48.7% to 11,700, while revenue per active earning coach rose 41.0% to $6,529. Cash, cash equivalents and investment securities totaled $169.8 million, and the company reported no debt. Market data providers noted the revenue and loss per share were better than consensus estimates. The results were accompanied by commentary from chief executive Nick Johnson, who said the company continued to see signs of a turnaround.

Key Business and Index Drivers

The capex angle is shaped by restructuring rather than growth spending. The earnings release did not disclose a capital expenditure figure. What it did describe is a cost program called Catalyst, launched in the second quarter with most execution expected in the third, aimed at savings through facility consolidation, AI-related efficiencies and other measures. Medifast also amended the lease on its Havre de Grace distribution facility, reducing square footage and extending the term. Strategically, the company is rebranding toward Trilivy, introducing the Trilivy Reset product line, and opening a Medifast Metabolic Health Institute under what it calls a 3.0 strategy. With a debt-free balance sheet, management retains flexibility, though a smaller coach base could limit the revenue these investments support.

What Investors Should Watch

Company guidance for the third quarter calls for revenue of $60 million to $80 million and a loss per share of $0.15 to $0.65, excluding one-time Catalyst costs. For full-year 2026, guidance is revenue of $270 million to $300 million and a loss per share of $0.25 to $1.75. Management has said it is on track to return to profitability in the fourth quarter, which remains a target rather than a certainty. Items that could matter include the pace of coach count stabilisation, the size of Catalyst savings versus one-time costs, any disclosure of capital spending in the quarterly filing, and how cash evolves from $169.8 million. The next earnings date has been estimated by data providers but not confirmed by the company. Any update to the lease footprint or distribution network could also provide clues on future capital needs.

Cost Cuts, a Rebrand and the Path Back to Profit

Medifast is trying to reset its business with a lean cost base, a new brand and a debt-free balance sheet. Whether lower capital intensity and Catalyst savings can offset falling revenue may be the defining issue in coming quarters.